Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities

Receptor tyrosine kinase (RTK) pathways serve as frequent oncogene drivers in solid cancers and small molecule and antibody-based inhibitors have been developed as targeted therapeutics for many of these oncogenic RTKs. In general, these drugs, when delivered as single agents in a manner consistent...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleczko, Emily K., Heasley, Lynn E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817864/
https://www.ncbi.nlm.nih.gov/pubmed/29458371
http://dx.doi.org/10.1186/s12943-018-0816-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817864/
https://www.ncbi.nlm.nih.gov/pubmed/29458371
http://dx.doi.org/10.1186/s12943-018-0816-y

Ejemplares similares